Freenome is a private biotech company developing blood tests for early cancer detection using a multiomics platform. It focuses on single-cancer and multi-cancer screening tests aimed at detecting cancer in its earliest, most treatable stages.
UpMarket does not offer Freenome shares. This page covers Freenome's history before it went public.
Latest Price
$1.1B
PIPE, 2025, Perplexity
UpMarket Estimate
$1.2B
Based on UpMarket valuation model
Previous Price
Series C Feb 2024
How to Review Freenome's Pre-IPO History on UpMarket
Freenome became a public company on July 21, 2026 and trades on Nasdaq as FRNM. UpMarket does not offer Freenome shares. This page covers Freenome's valuation and funding history before it went public.
Step 01
Check the listing details
Freenome listed on Nasdaq under the ticker FRNM on July 21, 2026.
Step 02
Review the valuation history
See how Freenome's private-market valuation changed across funding rounds before it went public.
Step 03
Review funding and revenue data
See reported funding rounds and revenue figures on this page, with their sources.
Step 04
Explore private companies
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
2025
PIPE
$10.00
$1.1B
Feb 2024
Series C
Dec 2021
Series D
Freenome Revenue and Growth
Annual revenue
Why Investors Are Watching Freenome
Growth Signal
Freenome added $254M in 2024 to fund early cancer tests
Freenome said it raised $254 million in new funding on Feb. 15, 2024, from new and existing investors to accelerate its platform for early cancer detection. Roche led the round, alongside a16z Life Sciences Growth Fund, Quest Diagnostics, RA Capital and others.
In January 2022, Roche invested $290 million in Freenome, bringing total funding to more than $1.1 billion since the company was founded in 2014. Roche had already been an investor since Freenome’s 2019 Series B, signaling repeat strategic support.
Market Opportunity
Freenome is building blood tests for multiple cancer types
Freenome describes its platform as a multiomics blood-testing system for early cancer detection through a routine blood draw. A 2022 Roche announcement said the investment would support expansion of Freenome’s products to additional cancers beyond colorectal screening.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
Yes. Freenome became a public company on July 21, 2026 and trades on Nasdaq under the ticker FRNM. UpMarket does not offer Freenome shares.
Freenome's share price is set on the public market under the ticker FRNM. The prices shown on this page are historical private-market prices from before it went public.
No. Freenome is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Freenome is now publicly traded, so its shares can be bought and sold on Nasdaq and their price can change significantly. Review Freenome's public filings and consult a financial advisor before investing. UpMarket does not offer Freenome shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Freenome became a public company on July 21, 2026, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.
UpMarket does not offer Freenome shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Freenome's valuation is now set by its public share price on Nasdaq. The figures on this page show its valuation history before it went public.
Freenome develops blood-based early cancer detection tests on a multiomics platform and reported $108.5M in 2024 revenue, after adding $254M in 2024 to fund its single-cancer and multi-cancer screening pipeline. Freenome is now a public company, and UpMarket does not offer its shares.